CVRx to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call

Rhea-AI Summary

CVRx, a medical device company, will release its third quarter financial results on November 4, 2021, after market close. A conference call to discuss these results is scheduled for 5:30 p.m. Eastern Time the same day. U.S. callers can dial (833) 730-3980, while international callers should use +1 (720) 405-2140, referencing conference code 6038756. CVRx is known for developing Barostim™, an FDA-approved neuromodulation device that helps heart failure patients by restoring balance to the autonomic nervous system.

MINNEAPOLIS, Oct. 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter financial and operating results after market close on Thursday, November 4, 2021. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same day.

To listen to the conference call on your telephone, please dial (833) 730-3980 for U.S. callers, or +1 (720) 405-2140 for international callers, approximately ten minutes prior to the start time and reference conference code 6038756. To listen to a live webcast, please visit the Investors section of the CVRx website at: ir.cvrx.com/investor-relations. The webcast replay will be available on the CVRx website for 12 months following completion of the call.

About CVRx, Inc.

CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the US. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:

Mark R. Klausner or Mike Vallie
Westwicke, an ICR Company
ir@cvrx.com

Media Contact:

Lisa Murray
Trevi Communications, Inc.
978.750.0333 / 617.835.0396
lisa@trevicomm.com

FAQ

When will CVRx release its third quarter financial results?

CVRx plans to release its third quarter financial results on November 4, 2021, after market close.

What time is the CVRx conference call on November 4, 2021?

The CVRx conference call to discuss third quarter results will be held at 5:30 p.m. Eastern Time on November 4, 2021.

How can I listen to the CVRx conference call?

To listen to the CVRx conference call, U.S. callers can dial (833) 730-3980 and international callers can use +1 (720) 405-2140, referencing conference code 6038756.

What is Barostim from CVRx?

Barostim is an FDA-approved medical device that uses neuromodulation to alleviate symptoms in heart failure patients by balancing the autonomic nervous system.

Is Barostim approved in Europe?

Yes, Barostim has received the CE Mark for treating heart failure and resistant hypertension in the European Economic Area.